Product Description
an inhaled small-molecule pan-selectin antagonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16140027/)
Mechanisms of Action: P-selectin Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Revotar
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Psoriasis|Chronic Obstructive Pulmonary Disease|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Stress Disorders, Post-Traumatic |
2020-06-29 |
|||
| 2009-017257-35 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2010-12-17 |
2022-03-13 |
Treatments |
|
| 2009-013163-18 | P2 |
Completed |
Healthy Volunteers |
2009-12-17 |
2022-03-13 |
Treatments |
|
| Psoriasis POC | P2 |
Completed |
Psoriasis |
2009-08-20 |
2022-03-12 |
Treatments |
|
| R013 | P2 |
Completed |
Psoriasis |
None |
2019-03-18 |
Treatments |
|
| R014 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
None |
2019-03-18 |
Treatments |
|
| R015 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
None |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/01/2023 |
PubMed |
Sulfatide-selectin signaling in the spinal cord induces mechanical allodynia. |
|
07/04/2022 |
PubMed |
Method article: an in vitro blood flow model to advance the study of platelet adhesion utilizing a damaged endothelium. |
|
10/30/2021 |
PubMed |
Lung-Derived Selectins Enhance Metastatic Behavior of Triple Negative Breast Cancer Cells. |